hh.sePublikasjoner
Endre søk
RefereraExporteraLink to record
Permanent link

Direct link
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
Cost of illness from the public payers' perspective in patients with ankylosing spondylitis in rheumatological care
Musculoskeletal Sciences, Department of Orthopedics, Lund University Hospital, Klinikgatan 22, SE-221 85 Lund, Sweden.
Musculoskeletal Sciences, Department of Orthopedics, Lund University Hospital, Klinikgatan 22, SE-221 85 Lund, Sweden.
Research and Development Centre, Spenshult Hospital for Rheumatic Diseases, Halmstad, Sweden.
Department of Rheumatology, Skåne University Hospital, Lund University, Lund, Sweden.
Vise andre og tillknytning
2010 (engelsk)Inngår i: Journal of Rheumatology, ISSN 0315-162X, E-ISSN 1499-2752, Vol. 37, nr 11, s. 2348-55Artikkel i tidsskrift (Fagfellevurdert) Published
Abstract [en]

OBJECTIVE: To estimate the incremental costs to public payers for patients with ankylosing spondylitis (AS) of working age compared with reference subjects from the general population.

METHODS: We investigated total costs for 3 years (2005-2007) in 116 outpatients under 66 years of age with AS attending rheumatological care in Malmö, Sweden. Mean (SD) age was 46 (11) years and mean (SD) disease duration was 24 (11) years. Two subjects per AS patient matched for age, sex, and residential area were selected from the Population Register to serve as a reference group. We retrieved data concerning sick leave, prescription drugs, and healthcare consumption from Swedish health-cost registers by the unique personal identification numbers.

RESULTS: The mean total cost for the 3-year period 2005-2007 was US $37,095 (SD $30,091) for patients with AS, and $11,071 (SD $22,340) for the reference group. The mean indirect cost was $19,618 and $5905, respectively. Mean cost for healthcare was $8998 for the AS patients and $4187 for the reference subjects, and mean cost for drugs was $8479 and $979, respectively. The patients with AS treated with biological therapy constituted 80% of the total drug cost, but just 40% of the cost for disability pension.

CONCLUSION: Patients with AS had 3-fold increase in costs compared to reference subjects from the general population, and the drug costs were almost 10 times as high. Production losses (indirect cost) represented more than half of total cost (53%).

sted, utgiver, år, opplag, sider
2010. Vol. 37, nr 11, s. 2348-55
HSV kategori
Identifikatorer
URN: urn:nbn:se:hh:diva-22242DOI: 10.3899/jrheum.100099PubMedID: 20716657OAI: oai:DiVA.org:hh-22242DiVA, id: diva2:622419
Tilgjengelig fra: 2013-05-21 Laget: 2013-05-21 Sist oppdatert: 2018-03-22bibliografisk kontrollert

Open Access i DiVA

Fulltekst mangler i DiVA

Andre lenker

Forlagets fulltekstPubMed

Personposter BETA

Bremander, Ann

Søk i DiVA

Av forfatter/redaktør
Bremander, Ann
I samme tidsskrift
Journal of Rheumatology

Søk utenfor DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric

doi
pubmed
urn-nbn
Totalt: 52 treff
RefereraExporteraLink to record
Permanent link

Direct link
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf